Gao Liuwei, Zhang Hua, Zhang Bin, Zhang Lianmin, Wang Changli
Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Oncotarget. 2017 Feb 28;8(9):15632-15641. doi: 10.18632/oncotarget.14921.
The aim of the present study was to investigate the prognostic value of the combination of preoperative platelet count (PLT) and mean platelet volume (MPV) in patients with primary operable non-small cell lung cancer (NSCLC). We retrospectively analysed data from 546 patients with NSCLC who underwent complete resection at our institution from 2006 to 2010. Patients' clinical characteristics and laboratory test data at initial diagnosis were collected. Both preoperative PLT and MPV (COP-MPV) were calculated on the basis of the data obtained using the recommended cut-off values of 300 × 109 L-1 and 11.0 fL, respectively. Patients with both an elevated PLT (≥300× 109 L-1) and a decreased MPV (<11.0 fL) were assigned a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively. Multivariate analysis of the 9 clinical laboratory variables selected by univariate analysis revealed that preoperative COP-MPV was a significantly independent prognostic factor for overall survival (OS) (hazard ratio, 1.775; 95% confidence interval, 1.500-2.101; P< 0.001) and disease-free survival (DFS) (hazard ratio, 1.719; 95% confidence interval, 1.454-2.033; P< 0.001). In subgroup analyses for tumour pathological stage (I/II/IIIA) patients, we found that the level of COP-MPV was significantly associated with OS and DFS in each subgroup (P< 0.001, P< 0.001, P<0.001 for OS and P<0.001, P< 0.001, P=0.001 for DFS, respectively). In conclusion, the preoperative COP-MPV is a promising predictor of postoperative survival in patients with NSCLC and could classify these patients into three independent groups before surgery.
本研究旨在探讨术前血小板计数(PLT)与平均血小板体积(MPV)联合检测对原发性可手术非小细胞肺癌(NSCLC)患者的预后价值。我们回顾性分析了2006年至2010年在我院接受根治性手术的546例NSCLC患者的数据。收集患者初诊时的临床特征和实验室检查数据。术前PLT和MPV(联合血小板参数 - MPV,COP - MPV)分别根据获得的数据,采用推荐的临界值300×10⁹/L⁻¹和11.0 fL进行计算。PLT升高(≥300×10⁹/L⁻¹)且MPV降低(<11.0 fL)的患者得分为2分,表现为其中一项异常或无异常的患者分别得分为1分或0分。对单因素分析选出的9个临床实验室变量进行多因素分析,结果显示术前COP - MPV是总生存期(OS)(风险比,1.775;95%置信区间,1.500 - 2.101;P<0.001)和无病生存期(DFS)(风险比,1.719;95%置信区间,1.454 - 2.033;P<0.001)的显著独立预后因素。在肿瘤病理分期(I/II/IIIA)患者的亚组分析中,我们发现每个亚组中COP - MPV水平均与OS和DFS显著相关(OS分别为P<0.001、P<0.001、P<0.001;DFS分别为P<0.001、P<0.001、P = 0.001)。总之,术前COP - MPV是NSCLC患者术后生存的一个有前景的预测指标,并且可以在术前将这些患者分为三个独立组。